Researchers from the PTSD Systems Biology Consortium, led by scientists from the Walter Reed Army Institute of Research, have identified distinct biotypes for post-traumatic stress disorder, the first of their kind for any psychological disorder. “These biotypes can refine the development of screening tools and may explain the varying efficacy of PTSD treatments”, said Dr. Marti Jett, leader of the consortium and WRAIR chief scientist.
Scientists at the Walter Reed Army Institute for Research recently demonstrated that brain-related proteins are linked to low levels of overpressure exposure from weapons and explosives used in training.
Scientists at the Walter Reed Army Institute for Research have shown that microRNA biomarkers related to Alzheimer’s disease play a role in brain damage caused by traumatic brain injury.
Though the COVID-19 pandemic remains a top priority for the U.S. Army and government’s healthcare and medical research apparatus, SARS-CoV-2 is just one of many ongoing infectious disease-related public health concerns. Antibiotic-resistant bacteria remain a significant threat to the public as well as Service Members, on and off the battlefield.
Scientists at the Walter Reed Army Institute for Research and Army Research Laboratory have developed a computer-based training to reduce anger, reactive aggression and hostile attribution bias—the tendency to attribute hostile intent to the actions of others—in ambiguous social conflict situations.
Scientists at the Walter Reed Army Institute for Research have recently demonstrated that cathepsin B, a well-studied protein important to brain development and function, can be used as biomarker, or indicator of severity, for traumatic brain injury.
Infecting some volunteers with COVID-19 may provide valuable insights for future rounds of vaccine testing, but would require very strict controls, argues a group of infectious disease experts in the New England Journal of Medicine.
The U.S. Army Medical Research and Development Command announced today that the U.S. Food and Drug Administration granted marketing approval for Artesunate for Injection, an initial treatment for severe malaria.
Scientists from the Walter Reed Army Institute of Research joined partners at Duke University, Florida Atlantic University and Montana State University to publish a study in Science providing clear evidence that malaria’s characteristic cycle of fever and chills is a result of the parasite’s own influence—not factors from the host.